S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Bank Accounts: Frozen! (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Bank Accounts: Frozen! (Ad)
Travel disruption hits Germany on eve of transport strike
Biden's pick to lead FAA withdraws amid shaky Senate support
Bank Accounts: Frozen! (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Bank Accounts: Frozen! (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Bank Accounts: Frozen! (Ad)
Travel disruption hits Germany on eve of transport strike
Biden's pick to lead FAA withdraws amid shaky Senate support
Bank Accounts: Frozen! (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Bank Accounts: Frozen! (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Bank Accounts: Frozen! (Ad)
Travel disruption hits Germany on eve of transport strike
Biden's pick to lead FAA withdraws amid shaky Senate support
Bank Accounts: Frozen! (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Bank Accounts: Frozen! (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Bank Accounts: Frozen! (Ad)
Travel disruption hits Germany on eve of transport strike
Biden's pick to lead FAA withdraws amid shaky Senate support
Bank Accounts: Frozen! (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
Positive News Sentiment  
NASDAQ:PROK

ProKidney - PROK Stock Forecast, Price & News

$12.62
+1.67 (+15.25%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$10.96
▼
$13.21
50-Day Range
$8.43
▼
$13.78
52-Week Range
$5.14
▼
$14.19
Volume
433,888 shs
Average Volume
N/A
Market Capitalization
$323.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.20

ProKidney MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
20.4% Upside
$15.20 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.89) to ($0.67) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.75 out of 5 stars

Medical Sector

838th out of 1,005 stocks

Biological Products, Except Diagnostic Industry

147th out of 168 stocks

See Top Rated MarketRank™ Stocks Here

PROK stock logo

About ProKidney (NASDAQ:PROK) Stock

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Receive PROK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProKidney and its competitors with MarketBeat's FREE daily newsletter.

PROK Stock News Headlines

March 3, 2023 | finance.yahoo.com
ProKidney to Participate in TD Cowen’s 43rd Annual Health Care Conference
February 21, 2023 | morningstar.com
ProKidney Corp Ordinary Shares - Class A
March 26, 2023 | Behind the Markets (Ad)
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
January 11, 2023 | finance.yahoo.com
ProKidney’s stock jumps 29%
January 10, 2023 | msn.com
ProKidney surges 20% on cell therapy potential to slow dialysis for chronic kidney disease
January 10, 2023 | finance.yahoo.com
ProKidney Announces Publication of Trial Design for Phase 2 Multicenter Clinical Trial of REACT for Late Stage 4 Diabetes-Related Chronic Kidney Disease
December 27, 2022 | finance.yahoo.com
A Look At The Intrinsic Value Of ProKidney Corp. (NASDAQ:PROK)
December 22, 2022 | finance.yahoo.com
ProKidney to Present at the J.P. Morgan 41st Annual Healthcare Conference
March 26, 2023 | Behind the Markets (Ad)
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
December 17, 2022 | money.usnews.com
ProKidney Corp - Ordinary Shares - Class A
November 16, 2022 | finance.yahoo.com
ProKidney (NASDAQ:PROK) Is In A Good Position To Deliver On Growth Plans
November 15, 2022 | bizjournals.com
Winston-Salem clinical-stage company reports increase in cash, expenses during Q3 as result of going public
November 14, 2022 | finance.yahoo.com
ProKidney Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
November 12, 2022 | finance.yahoo.com
ProKidney to Participate in Upcoming Investor Conferences
November 3, 2022 | finance.yahoo.com
ProKidney Receives Allowance from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for proact 1 (REGEN-006) and EMA Scientific Advice on Phase 3 Protocols of REACT for Diabetic Chronic Kidney Disease
October 15, 2022 | benzinga.com
ProKidney Announces Multiple Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2022
October 14, 2022 | finance.yahoo.com
ProKidney Announces Multiple Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2022
October 14, 2022 | benzinga.com
Citigroup Initiates Coverage On ProKidney with Buy Rating, Announces Price Target of $16
September 8, 2022 | finance.yahoo.com
ProKidney to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
August 31, 2022 | finance.yahoo.com
ProKidney Appoints Glenn Schulman, PharmD, MPH, as Senior Vice President of Investor Relations
August 11, 2022 | finance.yahoo.com
ProKidney Corp. Reports Second Quarter 2022 Financial Results and Provides Business Update
July 28, 2022 | finance.yahoo.com
ProKidney Corp. (PROK)
July 27, 2022 | finance.yahoo.com
ProKidney Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs
See More Headlines
Receive PROK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProKidney and its competitors with MarketBeat's FREE daily newsletter.

PROK Company Calendar

Today
3/26/2023
Next Earnings (Estimated)
3/27/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PROK
CUSIP
N/A
CIK
1850270
Web
www.prokidney.com
Phone
336-999-7028
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.20
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+20.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
52.78
Quick Ratio
52.78

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.33) per share
Price / Book
-38.24

Miscellaneous

Outstanding Shares
25,640,000
Free Float
14,205,000
Market Cap
$323.58 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Dr. Timothy A. Bertram D.V.M. (Age 67)
    Ph.D., Founder, CEO & Director
  • Mr. James Coulston CPA (Age 46)
    Chief Financial Officer
  • Dr. Deepak Jain Ph.D. (Age 68)
    Chief Operating Officer
  • Dr. Glenn Schulman M.P.H.
    Pharm. D., Pharm.D., Sr. VP of Investor Relations
  • Mr. Todd C. Girolamo Esq. (Age 57)
    J.D., M.B.A., Chief Legal Officer & Corp. Sec.
  • Dr. Libbie P. McKenzie M.D. (Age 49)
    Chief Medical Officer
  • Ms. Ashley H. Johns
    Sr. VP of Clinical Operations
  • Dr. Joseph M. Stavas M.D.
    Sr. VP of Clinical Devel.
  • Dr. Darin J. Weber Ph.D. (Age 54)
    Sr. VP of Regulatory Devel.
  • Dr. Kerry Cooper M.D.
    Sr. VP of Medical Affairs

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













PROK Stock - Frequently Asked Questions

Should I buy or sell ProKidney stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ProKidney in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PROK shares.
View PROK analyst ratings or view top-rated stocks.

What is ProKidney's stock price forecast for 2023?

6 Wall Street research analysts have issued 12-month price objectives for ProKidney's shares. Their PROK share price forecasts range from $13.00 to $18.00. On average, they anticipate the company's stock price to reach $15.20 in the next year. This suggests a possible upside of 20.4% from the stock's current price.
View analysts price targets for PROK or view top-rated stocks among Wall Street analysts.

How have PROK shares performed in 2023?

ProKidney's stock was trading at $6.86 at the beginning of 2023. Since then, PROK shares have increased by 84.0% and is now trading at $12.62.
View the best growth stocks for 2023 here.

When is ProKidney's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our PROK earnings forecast.

What is ProKidney's stock symbol?

ProKidney trades on the NASDAQ under the ticker symbol "PROK."

Who are ProKidney's major shareholders?

ProKidney's stock is owned by a number of retail and institutional investors. Top institutional investors include Social Capital Group LLC (51.77%), Morgan Stanley (42.70%), Brown University (3.90%), Bank of America Corp DE (0.77%), Geode Capital Management LLC (0.52%) and Swiss National Bank (0.29%).

How do I buy shares of ProKidney?

Shares of PROK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ProKidney's stock price today?

One share of PROK stock can currently be purchased for approximately $12.62.

How much money does ProKidney make?

ProKidney (NASDAQ:PROK) has a market capitalization of $323.58 million.

How can I contact ProKidney?

ProKidney's mailing address is 2850 W. HORIZON RIDGE PARKWAY SUITE 200, HENDERSON NV, 89052. The official website for the company is www.prokidney.com. The company can be reached via phone at 336-999-7028 or via email at lroth@burnsmc.com.

This page (NASDAQ:PROK) was last updated on 3/26/2023 by MarketBeat.com Staff